Alaunos Therapeutics Inc (STU:WEK)
€ 1.66 0 (-4.82%) Market Cap: 338.23 Mil Enterprise Value: 276.94 Mil PE Ratio: 0 PB Ratio: 1.04 GF Score: 54/100

ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:30PM GMT
Release Date Price: €4.52 (+3.67%)
Eric William Joseph
JP Morgan Chase & Co, Research Division - VP & Senior Analyst

Great. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is ZIOPHARM Oncology. And to talk to us a little bit about the company is CEO, Larry Cooper -- sorry, Laurence Cooper. My mistake. The breakout session with the Q&A will be in the Yorkshire room. With that, Laurence.

Laurence James Neil Cooper
ZIOPHARM Oncology, Inc. - CEO & Director

Thanks very much, Eric, and greetings from San Francisco. Forward-looking statements and additional information on our website.

Ziopharm is an independent, and we stress independent, immuno-oncology company focused on developing individualized and cost-effective therapies primarily aimed at the large and unmet needs in solid tumors. The key words on there are independent and that we are focused on solid tumors as we move forward, and I'll get into the technical reasons and the programmatic reasons of why we're so bullish on our company.

We have technologies that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot